Prof. Milena Georgieva, PhD

Professor of Molecular Biology | Co-founder and Chief Scientific Officer, Epix AI

Prof. Milena Georgieva is a molecular biologist and epigeneticist with more than two decades of research and leadership experience in molecular genetics, epigenetics, and longevity science. She is a Full Professor at the Institute of Molecular Biology, Bulgarian Academy of Sciences, where she leads the Laboratory of Molecular Genetics, Epigenetics, and Longevity. Her scientific work focuses on genome stability, chromatin structure, and the molecular mechanisms of aging.

She has authored and co-authored over one hundred peer-reviewed scientific publications and has led numerous national and international research projects, including several funded under the EU Horizon 2020 and Bulgarian Science Fund programs. Prof. Georgieva's expertise extends into translational science and innovation — she is the Co-Founder and Chief Scientific Officer of Epix AI, a pioneering longevity technology company integrating epigenetic biomarkers with artificial intelligence to design hyperpersonalized health and longevity strategies.

Beyond academia, Prof. Georgieva actively bridges science, communication, and policy. She co-founded and chairs the Bulgarian Longevity Society and is a Co-Founder and Science Director of the STEAM & Space Cluster at the Atlantic Club of Bulgaria, advancing interdisciplinary innovation at the intersection of biology, technology, and space research. She also serves as an External Scientific Advisor for the EU Horizon LifeSaver project, a Reviewer Panel Member for the Research Foundation – Flanders (FWO), and a Health Expert at AcrossLimits (Malta).

A recognized science communicator, Prof. Georgieva is a frequent speaker at global forums such as WebIt, PowerSummit, and Delphi Economic Forum, and has appeared on TEDx, national media, and science festivals to translate cutting-edge research into accessible knowledge. Her memberships include the European Federation of Biochemical Societies, the International Union of Clinical Epigenetics, and the Union of Scientists in Bulgaria.

Through her academic and entrepreneurial work, Prof. Georgieva continues to drive the integration of molecular biology, AI, and personalized medicine toward the future of "Longevity by Design."

Epix AI – Company profile

Epix AI is pioneering the intersection of epigenetics and artificial intelligence to revolutionize how we understand and combat aging. By integrating whole genome sequencing with high-density methylation arrays, the company generates precise measurements of biological age—far more accurate than chronological years—and quantifies risks for age-related diseases like Alzheimer's, cardiovascular conditions, and diabetes. These epigenetic clocks reveal how lifestyle, environment, and genetics accelerate or decelerate cellular aging, empowering people to make the right life choices to extend their health span.

Operating in a B2B2C model, Epix AI partners with longevity clinics. Its advanced analytics platform processes client biometric data, delivering personalized risk profiles and biological age reports. Clinicians use these insights to guide patients toward targeted interventions—

hormone optimization, senolytic therapies, or advanced nutraceuticals—designed to reverse agin markers and extend health span.

Looking ahead, Epix AI is developing digital twins that fuse real-time inputs from wearable devices, geolocation tracking, and lifestyle logs. Enhanced by agentic AI, these virtual models simulate an individual's aging trajectory under different scenarios, extracting critical insights from unstructured data such as sleep patterns, stress biomarkers, and environmental exposures. This predictive layer enables proactive, hyper-personalized recommendations—adjusting diet before inflammation spikes or flagging urban pollution risks in real time.

By transforming complex molecular data into intuitive, clinic-ready intelligence, Epix AI is not just measuring aging—it's engineering longer, healthier lives. For longevity clinics and their clients, it shifts longevity medicine from reactive to preventive, where every decision is informed by the body's deepest biological signals.